China’s brain-computer interface (BCI) sector is experiencing rapid advancement, positioning the country as a global contender in this transformative field, even as Elon Musk’s Neuralink emphasizes its pioneering role. Unlike the U.S., where BCI development remains largely in early clinical stages, China is swiftly transitioning from research to commercialization, driven by strong government backing, extensive clinical resources, mature manufacturing infrastructure, and rising private investment. Phoenix Peng, a dual-founder of implantable BCI company NeuroXess and noninvasive ultrasound BCI startup Gestala, underscores the sector’s momentum. He highlights that provinces like Sichuan, Hubei, and Zhejiang have already established medical pricing for BCI treatments, paving the way for inclusion in national health insurance—accelerating market adoption. A national roadmap unveiled in August 2025 by China’s industry ministry and six other agencies sets ambitious targets: achieving key technical milestones by 2027, establishing industry-wide standards, and building a complete domestic supply chain by 2030. This strategic push is supported by a 11.6 billion yuan ($165 million) brain science fund announced at the 2025 Shenzhen BCI & Human-Computer Interaction Expo. The policy environment fosters cross-departmental coordination, harmonizing technical standards and reimbursement pathways—unlike the fragmented insurance systems in the U.S. and Europe’s stringent regulatory frameworks. China’s vast patient population and lower research costs enable faster clinical trials. By mid-2025, over 50 flexible, implantable BCI trials had been completed, focusing on motor recovery, language decoding, stroke rehabilitation, and spinal cord repair. China also achieved the country’s first fully implanted, wireless BCI trial—only the second globally—allowing a paralyzed patient to control devices without external hardware, a milestone previously reached only by Neuralink. Meanwhile, next-generation efforts are exploring whole-brain decoding and novel noninvasive methods like ultrasound, exemplified by Gestala’s technology. China’s advanced semiconductor, AI, and medical hardware industries enable rapid prototyping and scaling. This industrial strength, combined with surging investment, has fueled major funding rounds: StairMed Technology raised $48 million in Series B, BrainCo secured $287 million and filed for a Hong Kong IPO, and Gestala is closing an angel round. Key players include NeuroXess, Neuracle, NeuralMatrix, BrainCo, and Zhiran Medical, which uses flexible electrodes to reduce inflammation and improve long-term implant performance. BCI technologies fall into two main categories: invasive electrophysiological systems (e.g., NeuroXess, Neuralink) that offer high precision but require surgery, and noninvasive systems (e.g., BrainCo, NeuroSky) that prioritize safety and accessibility. Emerging modalities—ultrasound, transcranial magnetic stimulation, optical imaging, and hybrid systems—are expanding the field’s potential. Gestala’s ultrasound BCI, for instance, reduced chronic pain scores by 50% in early trials, with effects lasting up to two weeks—offering scalable, patient-friendly solutions. Looking ahead, China aims to align its BCI regulations with international standards (IEC, ISO, FDA guidance), tightening oversight on invasive devices and data privacy while streamlining approval for noninvasive tech. Ethical frameworks will be strengthened, with enhanced informed consent and broader ethics review beyond clinical medicine. As Peng envisions, BCI’s future extends beyond treating disease to human augmentation—bridging biological and artificial intelligence in a market poised to exceed 120 billion yuan by 2040. Industry insiders view China’s BCI trajectory as a strategic convergence of policy, innovation, and infrastructure, setting the stage for global leadership.